English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

According to statistics from America and Europe, the prognosis of pancreatic cancer (PC) is very poor, ranking it the fourth leading cause of cancer deaths (1). Pancreatectomy is the only effective method to cure this disease, but only 20% of patients are provided with the opportunity to resect the cancer tissue (2). Despite all these efforts, most of the patients are known to relapse (3). Distant metastasis is a major cause of death in cancer patients, especially with respect to PC. Only few cases do not show resistance to chemoor radiation therapy (4). Patients with metastatic disease have a median survival of 6 months and a 5-year survival rate of 1%, whereas treatment with surgical resection and other therapeutic approaches is associated with 12–22 months of median survival and a 5-year survival rate of 20–25% (5). Hence, PC poses one of the greatest challenges in cancer research. Nevertheless, our increasing knowledge on the development Original Article

Polo-like kinase 1 is involved in apoptosis, invasion, and metastasis of pancreatic ductal adenocarcinoma